DementiaDigital healthDevice
What this study is
The purpose of this research is to learn whether the HiDO-ALZ device can improve medication compliance and health outcomes in participants with dementia that need to take daily medication.
What's being tested
- HiDO HomeCareSystem
Intervention · DEVICE
Participants randomized to the intervention arm will receive and be trained on the HiDO HCS Device and will have medication dispensed via this technology.
Study details
- Official title
- Preventing Medication Mismanagement in People Living With Dementia Through Automated Medication Dispensing With Facial Recognition and Video Observation
- Sponsor
- HiDO Technologies
- Conditions
- Dementia
- Enrolling
- 50 people
- Starts
- 2026-05-05
- Est. completion
- 2027-12-31
- Design
- Open-label, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 65 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Participants must have a diagnosis of dementia.
- They must be prescribed one medication indicated for dementia symptoms such as Aricept, Namenda, or Donepezil, and be prescribed at least one additional medication.
- Participants must have an active study partner that is willing to be enrolled into the study and willing to receive messages and alerts from the HiDO-ALZ system if medications are missed. The study partner must also agree to complete surveys about the participant's ongoing health.
- Participants must be willing to allow research staff to enter their homes to install the HiDO-ALZ device and to complete study activities. The participant's medications will be reviewed by the UCD pharmacist prior to randomization. If a participant has contraindicated medication(s), this medication will need to be removed or justified by the prescribing clinician prior to randomization. The research team and HiDO staff will work with the UCD pharmacist and prescribing clinician to resolve contraindicated medications prior to randomization. If a resolution is not possible, the participant will not be enrolled. •MoCA score of 15 to 22 or previous MMSE score of 21 to 26 within the last 6 months. If no test is available, the participants will be given a MoCA test after signing consent to confirm eligibility.
You can't join if
- The inability to demonstrate capacity to consent or assent as determined by the Capacity Assessment Checklist.
- Individuals who do not have a study partner/caregiver (e.g., spouse, adult child) to complete questionnaires.
- Participants with MoCA scores below 15 will be excluded as they may not be able to use the device independently.
- Participants who are unable or unwilling to complete the cognitive testing or unwilling to complete the blood tests.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openHiDO Technologies
Folsom, California, United States
- Charles Gellman · Contact5138137224charles@hidohealth.com
- Lisa Marceau · Contact4014284197lmarceau@alphamhealth.com
- Charles Gellman · Principal investigator
Recruiting
Study team
Sponsor
HiDO Technologies
Study ID 5R44AG077737-03
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.